anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
That month, Amnesty International published their report, finding that Gaddafi's forces were responsible for numerous war crimes but added that a number of allegations of human rights abuses lacked credible evidence. The report added that "much Western media coverage has from the outset presented a very one-sided view of the logic of events, portraying the protest movement as entirely peaceful and repeatedly suggesting that the regime's security forces were unaccountably massacring unarmed demonstrators". In July, over 30 governments recognized the NTC as the legitimate government of Libya; Gaddafi called on his supporters to "Trample on those recognitions, trample on them under your feet ... They are worthless". In August, the Arab League recognized the NTC as "the legitimate representative of the Libyan state". Aided by NATO air cover, the rebel militia pushed westward, defeating loyalist armies and securing control of the centre of the country. Gaining the support of Amazigh (Berber) communities of the Nafusa Mountains, who had long been persecuted as non-Arabic speakers under Gaddafi, the NTC armies surrounded Gaddafi loyalists in several key areas of western Libya. In August, the rebels seized Zliten and Tripoli, ending the last vestiges of Gaddafist power. It is probable that without the NATO air strikes supporting the rebels, they would not have been able to advance west and Gaddafi's forces would have ultimately retaken control of eastern Libya.
=== Ha–He === James Haber (b. 1943). American molecular biologist at Brandeis University known for his discoveries in the field of DNA repair. Member Natl. Acad. Sci. USA. J. B. S. Haldane (John Burdon Sanderson Haldane, 1892–1964). British (and later Indian) geneticist, biochemist (study of enzymes) and statistician, at University College London and at the end of his life at the Indian Statistical Institute. Apart from his contributions to science, he was notable for political activism and wrote many articles for the Daily Worker. Gordon Hammes (b. 1934). American biochemist at Cornell and Duke University, noted for work on enzyme mechanisms and kinetics. Member Natl. Acad. Sci. USA. Philip Handler (1917–1981). American nutritionist and biochemist, noted for the understanding of nicotinic acid deficiency and the discovery of the tryptophan-nicotinic acid relationship. He was at Duke University until he became President of the Natl. Acad. Sci. USA Jean Hanson (1919–1973). British biophysicist and zoologist at Massachusetts Institute of Technology known for her contributions to muscle research. Arthur Harden FRS (1865–1940). British biochemist at the Lister Institute, known for work on the fermentation of sugar and fermentative enzymes. Nobel Prize in Chemistry (1929). Grahame Hardie FRS (b. 1950), British biochemist at the University of Dundee, known for work on AMP-activated protein kinase. Harry Harris FRS, FCRP (1919–1994), British-born biochemist who showed that human genetic variation was not rare. Edwin B.
Double-decker bus The approximate volume of a double-decker bus, abbreviated to DDB, has been used informally to describe the size of hole created by a major sewer collapse. For example, a report might refer to "a 4 DDB hole". Olympic-size swimming pool For larger volumes of liquid, one measure commonly used in the media in many countries is the Olympic-size swimming pool. A 50 m × 25 m (164 ft × 82 ft) Olympic swimming pool, built to the FR3 minimum depth of 2 metres (6.6 ft) would hold 2,500 m3 (660,000 US gal). The US National Institute of Standards and Technology (NIST) defines the Olympic swimming pool as 1 million litres, which is the approximate volume of the smaller FR2 pool. Royal Albert Hall The Royal Albert Hall, a large concert hall, is sometimes used as a unit of volume in the UK, for example when referring to volumes of rubbish placed in landfill. It is famously used in the line "Now they know how many holes it takes to fill the Albert Hall." in The Beatles song "A Day in the Life". The volume of the auditorium is between 3 and 3.5 million cubic feet (between 85,000 and 99,000 cubic metres). Melbourne Cricket Ground A common measure of volume in Australia, and in the state of Victoria in particular, is the Melbourne Cricket Ground, the largest stadium in Australia and 13th largest in the world. The volume of the Melbourne Cricket Ground is 1,574,000 cubic metres, or about 630 Olympic swimming pools. Its seating capacity (100,000 as of July 2019) is also used as a unit measure of the number of people.
Sources: en.wikipedia.org
== Efficacy == Hydrocolloid has been shown to be superior to other dressing substrates (e.g., alginate, film, gauze, hydrofiber, or silicone) tested for treating skin-graft donor sites. There is tentative but unclear (as of 2013) evidence for the efficacy of hydrocolloid dressings for superficial and partial-thickness burns. The results of meta-analyses indicate no significant difference in healing rates between hydrocolloid dressings and other dressings (including simple gauze dressings) for venous ulcers, or for diabetic foot ulcers.
THC is a weak partial agonist at CB1 receptors, while CBD is a CB1 receptor antagonist. The CB1 receptor is found primarily in the brain as well as in some peripheral tissues, and the CB2 receptor is found primarily in peripheral tissues, but is also expressed in neuroglial cells. THC appears to alter mood and cognition through its agonist actions on the CB1 receptors, which inhibit a secondary messenger system (adenylate cyclase) in a dose-dependent manner. Via CB1 receptor activation, THC indirectly increases dopamine release and produces psychotropic effects. CBD also acts as an allosteric modulator of the μ- and δ-opioid receptors. THC also potentiates the effects of the glycine receptors. It is unknown if or how these actions contribute to the effects of cannabis.
== Career == He joined the Department of Pharmacology of Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, on 14 April 1964 as Professor and Founder Chairman Department of Pharmacology. He served a period as Head Department of Pharmacology till 30 September 1985 and in view of his outstanding merits, he was re-employed by the University for the two years to 30 September 1987. Soon after retirement, he was selected as emeritus scientist of the ICMR, New Delhi, for a period from 1 September 1987, which he served till 14 September 1990. On 31 January 1991, the University appointed him as professor emeritus. In the university, he had also acted as Dean, Faculty of Medicine, In-charge, Animal House and on few occasions as acting Principal Ajmal Khan Tibbiya College and acting Vice Chancellor of the University. As a Professor Emeritus, he continued his active research in the Department of Pharmacology till late December 1994.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.